Merck (MRK +2.94%) stock has become dependent on its diabetes drug Januvia over the past couple of years for revenue growth. The franchise made up 12% of Merck's sales in the first quarter and ...

(The Center Square) – Negotiated lower Medicare costs for 10 popular prescription drugs went into effect Thursday. How much those savings will be passed on to Medicare Part D and applicable Advantage ...

After years of battling over the patents on blockbuster diabetes drug Januvia, Merck and its generic rival Viatris are ready to put the case to rest. In a recent filing with the U.S. District Court ...

Merck has filed applications with the FDA for two additional uses for its diabetes treatment Januvia. Merck is seeking approval for Januvia for the added indications as an adjunct to diet and exercise ...

In terms of controlling Type 2 diabetes and potentially obesity, Boston’s Intarcia Therapeutics just released some impressive Phase 3 findings: Its implantable device has been found to be more ...

Merck's juggernaut diabetes drug Januvia now faces renewed scrutiny five years after an endocrinologist found that lab rats given the medicine were more susceptible to pancreatic cancer, according to ...

DEAR DR. ROACH: Is Januvia an effective drug for diabetes? What are the side effects? — M.A.A. ANSWER: Sitagliptin (Januvia) is an oral medication for diabetes mellitus. The way it works is ...

Januvia, a widely used diabetes drug that generates $6 billion in annual sales for maker Merck, does not increase patients’ risk of being hospitalized for heart failure, a risk that did show up in ...

BOSTON (Reuters) - Eli Lilly and Co and Amylin Pharmaceuticals Inc said on Tuesday that a trial of their diabetes drug Byetta, which was recently linked with six deaths from pancreatitis, reduced ...

DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/q7v2fq/januvia_type_2) has announced the addition of the "Januvia (Type 2 ...

When I last wrote about the makers of Byetta and Januvia, two leading diabetes drugs, I called them the Hatfields and McCoys of diabetes care. Good call, that one. The two manufacturers, Amylin ...